Stock Events

Stock Events

TC BioPharm (Holdings) 

$0.5
53
-$1.04-67.53% Friday 20:00

Statistics

Day High
0.5
Day Low
0.5
52W High
480
52W Low
0.08
Volume
5,896,474
Avg. Volume
365,248
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

12DecExpected
Q4 2021
Q3 2022
-9.37
-8.08
-6.79
-5.5
Expected EPS
-5.5
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-4.2MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TCBP. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Allogene Therapeutics
ALLO
Mkt Cap275.13M
Allogene Therapeutics, Inc. works on allogeneic CAR T therapies for cancer, competing in the cell therapy space.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics AG is involved in gene editing and cell therapy for cancer, directly competing in the innovative treatment space.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, Inc. has a strong presence in cell therapy for cancer through its subsidiary Kite Pharma, making it a direct competitor.
Novartis
NVS
Mkt Cap237.61B
Novartis AG has approved CAR T-cell therapies in the market, making it a leading competitor in the cell therapy space.
Precigen
PGEN
Mkt Cap1.46B
Precigen, Inc. focuses on gene and cell therapies, including CAR T-cell therapies, competing in the same innovative treatment sector.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics, Inc. works on gene editing and cell therapy, which are key areas of competition with TC BioPharm.

About

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
Show more...
CEO
Mr. Bryan Leland Kobel
Employees
41
Country
GB
ISIN
US87807D6085

Listings

OTC Link
US
TCBPY
OTC Link
US
TCBWF
F
DE
T0U.F

0 Comments

Share your thoughts

FAQ

What is TC BioPharm (Holdings) stock price today?▼
The current price of TCBP is $0.5 USD — it has decreased by -67.53% in the past 24 hours. Watch TC BioPharm (Holdings) stock price performance more closely on the chart.
What is TC BioPharm (Holdings) stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange TC BioPharm (Holdings) stocks are traded under the ticker TCBP.
What is TC BioPharm (Holdings) revenue for the last year?▼
TC BioPharm (Holdings) revenue for the last year amounts to 0 USD.
What is TC BioPharm (Holdings) net income for the last year?▼
TCBP net income for the last year is -4.2M USD.
How many employees does TC BioPharm (Holdings) have?▼
As of April 02, 2026, the company has 41 employees.
In which sector is TC BioPharm (Holdings) located?▼
TC BioPharm (Holdings) operates in the Health Care sector.
When did TC BioPharm (Holdings) complete a stock split?▼
The last stock split for TC BioPharm (Holdings) was on January 07, 2025 with a ratio of 1.25:1.
Where is TC BioPharm (Holdings) headquartered?▼
TC BioPharm (Holdings) is headquartered in Motherwell, GB.